natgillin/translations-raw huggingface dataset:
Cardiac-disorders
Srčne bolezni
Cardio-vascular effects and precautions
Srčno-žilni učinki in previdnostni ukrepi
Cardioactive medicinal products
Zdravila za bolezni srca
cardiomyopathies (including heart failure), ischaemic coronary artery disorders , arrhythmias (including atrial fibrillation), palpitations
kardiomiopatije (vključno s srčnim popuščanjem), ishemična obolenja koronarnih arterij, aritmije (vključno z atrijsko fibrilacijo), palpitacije
Cardiomyopathy Myocarditis
kardiomiopatija miokarditis
Cardiomyopathy*
kardiomiopatija
Cardiomyopathy*, arrhythmia*
kardiomiopatija*, aritmije
Cardiomyopathy, arrhythmia*
kardiomiopatija, aritmije
cardiomyopathy, congestive heart failure (see section 4.4), palpitations, arrhythmia, tachycardia
kardiomiopatija, kongestivno srčno popuščanje (glejte poglavje 4.4), palpitacije, aritmija, tahikardija
Cardiomyopathy, especially in the presence of cardiac failure
kardiomiopatija, še posebej v primeru srčnega popuščanja,
Cardiomyopathy, in particular when heart failure is present
kardiomiopatija, posebej ob prisotnem popuščanju srca,
Cardiomyopathy, in particular when heart failure is present.
kardiomiopatija, posebej ob prisotnem popuščanju srca
Cardiomyopathy, in particular when heart failure is present.
kardiomiopatija, posebej ob prisotnem popuščanju srca,
cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
kardiopulmonalnim toksičnim učinkom (s prezgodnjim zaprtjem arterioznega duktusa in pljučno hipertenzijo),
Cardiorespiratory arrest or sudden death was reported in 2.8% (15/538) of patients treated with necitumumab in combination with gemcitabine and cisplatin compared to 0.6% (3/541) of patients treated with chemotherapy alone.
O kardiorespiratornem zastoju ali nenadni smrti so poročali pri 2,8 % (15/538) bolnikov, zdravljenih z necitumumabom v kombinaciji z gemcitabinom in cisplatinom v primerjavi z 0,6 % (3/541) bolnikov, ki so bili zdravljeni le s kemoterapijo.
Cardiovascular
Bolezni srca in ožilja
Cardiovascular
Kardiovaskularne bolezni
Cardiovascular
Kardiovaskularni neželeni učinki
Cardiovascular
Kardiovaskularni sistem
Cardiovascular
Srce in ožilje
Cardiovascular
Srčno-žilni sistem
Cardiovascular
Srčno-žilni učinki
Cardiovascular
Srčnožilni učinki
Cardiovascular (CV) risk
Tveganje za bolezni srca in ožilja
Cardiovascular (CVS) adverse events, particularly arrhythmia, appeared to be correlated mostly with pre- existing CVS disease and prior therapy with cardiotoxic agents (see section 4.4).
Videti je bilo, da kardiovaskularni (KVS) neželeni pojavi, še posebej aritmija, statistično korelirajo predvsem z obstoječo KVS boleznijo in predhodno terapijo s kardiotoksičnimi snovmi (glejte poglavje
Cardiovascular (CVS) adverse events, particularly arrhythmia, appeared to be correlated mostly with pre- existing CVS disease and prior therapy with cardiotoxic agents (see section 4.4).
Videti je bilo, da kardiovaskularni (KVS) neželeni pojavi, še posebej aritmija, statistično korelirajo predvsem z obstoječo KVS boleznijo in predhodno terapijo s kardiotoksičnimi snovmi (glejte poglavje 4.4).
CARDIOVASCULAR AGENTS
ZDRAVILA ZA BOLEZNI SRCA IN OŽILJA
CARDIOVASCULAR AGENTS
ZDRAVILA ZA ZDRAVLJENJE BOLEZNI SRCA IN OŽILJA
Cardiovascular beta- blockers are expected to be associated with the greatest risk, but reports have also been received in patients using other beta- blockers.
Z največjim tveganjem naj bi bili povezani tisti antagonisti adrenergičnih receptorjev beta, ki delujejo na kardiovaskularni sistem, vendar so o težavah poročali tudi pri bolnikih, ki so uporabljali druge antagoniste adrenergičnih receptorjev beta.
Cardiovascular beta- blockers are expected to be associated with the greatest risk, but reports have also been received in patients using other beta-blockers.
Kardiovaskularni zaviralci receptorjev beta so lahko povezani z večjim tveganjem, vendar so poročali tudi o bolnikih, ki so uporabljali druge zaviralce receptorjev beta.
Cardiovascular beta- blockers are expected to be associated with the greatest risk, but reports have also been received in patients using other beta-blockers.
Z največjim tveganjem naj bi bili povezani tisti antagonisti adrenergičnih receptorjev beta, ki delujejo na kardiovaskularni sistem, vendar so o težavah poročali tudi pri bolnikih, ki so uporabljali druge antagoniste adrenergičnih receptorjev beta.
cardiovascular complications (affecting the heart and blood vessels) including heart attack, congestive heart failure, palpitations, blood vessel dilation, changes in your pulse rate including weak/absent pulse, heart stops beating, heart and breathing stop, blue discolouration of skin and/or mucous membranes due to lack of oxygen in the blood (cyanosis)
zapleti srca in ožilja (prizadenejo srce in ožilje), vključno s srčnim infarktom, kongestivno srčno popuščanje, palpitacije (občutek razbijanja srca), razširitev krvnih žil, spremembe hitrosti utripa, vključno s šibkim/odsotnim utripom, prenehanje utripanja srca, ustavitev srca in dihanja, modro obarvanje kože in/ali sluznic zaradi pomanjkanja kisika v krvi (cianoza)
Cardiovascular conditions (e.g. constriction of blood vessels in the lung).
bolezni srca in žilja (npr. zoženja krvnih žil v pljučih)
Cardiovascular conditions.
bolezni srca in žilja
Cardiovascular death, MI or stroke
Kardiovaskularna smrt, miokardni infarkt ali možganksa kap
Cardiovascular death, MI or stroke
Kardiovaskularna smrt, miokardni infarkt ali možganska kap
Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques.
Kardiopulmonalno depresijo je treba zdraviti z ekspanderji plazme, presornimi sredstvi, antiaritmičnimi sredstvi ali drugimi ustreznimi metodami.
Cardiovascular disease
kardiovaskularna bolezen
cardiovascular diseases such as ischaemic heart disease, tachyarrhythmia and severe hypertension,
rčnožilnimi boleznimi, na primer ishemično srčno boleznijo, tahiaritmijo in hudo hipertenzijo,
cardiovascular diseases, family history of cardiovascular disease, stroke or "mini" stroke, abnormal blood pressure
rčnožilne bolezni, srčnožilne bolezni v družini, možgansko kap ali "malo" kap, nenormalen
cardiovascular diseases, family history of cardiovascular disease, stroke or "mini" stroke, abnormal blood pressure
rčnožilne bolezni, srčnožilne bolezni v družini, možgansko kap ali "malo" kap, nenormalen krvni tlak,
cardiovascular diseases, family history of cardiovascular disease, stroke or "mini" stroke, abnormal blood pressure
rčnožilne bolezni, srčnožilne bolezni v družini, možgansko kap ali „malo” kap, nenormalen krvni tlak,
Cardiovascular disorder
srčno-žilne bolezni
Cardiovascular disorder (inc cardiogenic shock)
srčnožilne bolezni (vključno s kardiogenim šokom)
Cardiovascular disorders
Srčne in žilne bolezni
Cardiovascular disorders
Srčno-žilne bolezni
Cardiovascular Drugs, Miscellaneous
Kardiovaskularna zdravila, razno
Cardiovascular effects
Učinki na srce in ožilje
Cardiovascular effects:
Kardiovaskularni učinki:
Cardiovascular evaluation
Kardiovaskularni parametri
Cardiovascular events
Hjarta- og æðakvillar
Cardiovascular events reported during clinical studies were asymptomatic.
Kardiovaskularni dogodki, o katerih so poročali med kliničnimi preskušanji, so bili asimptomatski.
Cardiovascular events, including heart failure, cardiomyopathy, and myocardial ischemia and myocardial infarction, some of which were fatal, have been reported in patients treated with sunitinib.
Pri bolnikih, zdravljenih s sunitinibom, so poročali o srčno-žilnih dogodkih, vključno s srčnim popuščanjem, kardiomiopatijo, miokardno ishemijo in miokardnim infarktom, v nekaterih primerih s smrtnim izidom.
cardiovascular inability
kardiovaskularno popuščanje
Cardiovascular insufficiency Cardiac failure
kardiovaskularna insuficienca odpoved srca
Cardiovascular Medicinal Products
Kardiovaskularna zdravila
Cardiovascular prevention
Preprečevanje srčno-žilnih bolezni
Cardiovascular reactions
Srčno-žilni neželeni učinki
Cardiovascular risk
Tveganje za bolezni srca in ožilja
Cardiovascular safety
Srčnožilna varnost
Cardiovascular safety pharmacology studies in monkeys and dogs show that intravenous doses approximately two to three times the recommended clinical dose on a mg/m2 basis are associated with increases in heart rate, decreases in contractility, hypotension and death.
Farmakološka preskušanja kardiovaskularne varnosti zdravila pri opicah in psih kažejo povezavo med intravenskimi odmerki, ki so bili dva- do trikrat večji od priporočenega kliničnega odmerka (v mg/m2), in povišanjem srčne frekvence, zmanjšanjem kontraktilnosti srca, hipotenzijo in smrtjo.
Cardiovascular safety profile is characterized by the anticholinergic effects.
Za kardiovaskularni profil varnosti je značilen antiholinergični učinek.
Cardiovascular Safety – Long-Term Studies Involving Subjects With Sporadic Adenomatous Polyps: Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e., the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps).
Srčnožilna varnost – dolgoročne študije preiskovancev s sporadičnimi adenomatoznimi polipi: S celekoksibom sta bili izvedeni dve študiji preiskovancev s sporadičnimi adenomatoznimi polipi: preskušanje APC (Adenoma Prevention with Celecoxib) in preskušanje PreSAP (Prevention of Spontaneous Adenomatous Polyps).
Cardioversion (SPAF, DVT/PE)
Kardioverzija (SPAF, GVT/PE)
Cardioversion (SPAF, DVT/PE)
Kardioverzija (SPAF,GVT/PE)
Care for injection site
Nega mesta injiciranja
Care for the injection site
Nega mesta injiciranja
Care is taken to avoid bleeding.
Paziti je treba, da ne pride do krvavitve.
Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid (ASA) and platelet aggregation inhibitors.
Če bolniki sočasno prejemajo zdravila, ki vplivajo na hemostazo, npr. nesteroidna protivnetna zdravila (NSAID), acetilsalicilno kislino in zaviralce agregacije trombocitov, je potrebna previdnost.
Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid and platelet aggregation inhibitors.
Če bolniki sočasno prejemajo zdravila, ki vplivajo na hemostazo, npr. nesteroidna protivnetna zdravila (NSAID), acetilsalicilno kislino in zaviralce agregacije trombocitov, je potrebna previdnost.
Care is to be taken if patients are treated concomitantly with non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.
Previdnost je potrebna, kadar se bolniki sočasno zdravijo z nesteroidnimi protivnetnimi zdravili, vključno z acetilsalicilno kislino.
Care must be taken not to administer Bondronat concentrate for solution for infusion via intra-arterial or paravenous administration, as this could lead to tissue damage..
Paziti je treba, da koncentrata za raztopino za infundiranje zdravila Bondronat ne dajemo intraarterijsko ali paravensko, ker lahko to vodi v poškodbo tkiva.
Care must be taken not to administer Iasibon concentrate for solution for infusion via intra-arterial or paravenous administration, as this could lead to tissue damage..
Paziti je treba, da koncentrata za raztopino za infundiranje zdravila Iasibon ne dajemo intraarterijsko ali paravensko, ker lahko to vodi v poškodbo tkiva.
Care must be taken not to administer ibandronic acid concentrate for solution for infusion via intra- arterial or paravenous administration, as this could lead to tissue damage.
Paziti je treba, da koncentrata za raztopino za infundiranje zdravila Ibandronska kislina Accord ne dajemo intraarterijsko ali paravensko, ker lahko to vodi v poškodbo tkiva.
Care must be taken to avoid inadvertent injection of TREVICTA into a blood vessel.
Pazimo, da zdravila TREVICTA pomotoma ne injiciramo v žilo.
Care must be taken to e administer Iasibon concentrate for solution for infusion via intra-arterial or paravenous administration, as this could lead to tissue damage.
Paziti je treba, da koncentrata za raztopino za infundiranje zdravila Iasibon ne dajemo intraarterijsko ali paravensko, ker lahko to vodi v poškodbo tkiva.
Care must be taken to ensure that administer Iasibon concentrate for solution for infusion via intra- arterial or paravenous administration, as this could lead to tissue damage.
Paziti je treba, da koncentrata za raztopino za infundiranje zdravila Iasibon ne dajemo intraarterijsko ali paravensko, ker lahko to vodi v poškodbo tkiva.
Care must be taken to ensure that no alcohol or other disinfectants enter the insulin solution.
Paziti je treba, da v raztopino insulina ne pride alkohol ali kakšen drug dezinficiens.
Care must be taken when prescribing Rivastigmine 3M Health Care Ltd. transdermal patches:
Previdnost je potrebna pri predpisovanju transdermalnih obližev Rivastigmin 3M Health Care Ltd.:
Care must therefore be taken when handling Sevoflo: any spillage must be removed immediately, the vapour must not be inhaled, and all contact with the product by mouth must be avoided.
Pri ravnanju z zdravilom SevoFlo je zato potrebna posebna pozornost: morebitno razlito zdravilo je treba odstraniti takoj, hlapi se ne smejo vdihavati, prav tako pa se je treba izogibati vsakršnemu peroralnemu stiku z zdravilom.
Care should also be taken in populations that may have a higher maximum plasma concentration (Cmax) of anagrelide or its active metabolite, 3-hydroxy-anagrelide, e.g. hepatic impairment or use with CYP1A2 inhibitors (see section 4.5).
Previdnost je potrebna tudi pri skupinah bolnikov, ki utegnejo imeti višjo maksimalno plazemsko koncentracijo (Cmax) anagrelida ali njegovega aktivnega presnovka 3-hidroksi-anagrelida, n.pr. pri bolnikih z okvarami jeter ali pri uporabi skupaj z zaviralci CYP1A2 (glejte poglavje 4.5).
Care should also be taken when switching from other basal insulins to Toujeo or vice versa as the dose of insulin may need to be adjusted.
Previdnost je potrebna tudi pri prehodu z drugih osnovnih insulinov na zdravilo Toujeo ali obratno, saj bo morda treba odmerek insulina prilagoditi.
Care should also be taken when used with medicines which have an effect on the kidney such as diuretics.
Previdnost je potrebna tudi pri uporabi skupaj z zdravili, ki učinkujejo na ledvice, kot so diuretiki.
Care should also be taken when used with molecules displaying action on renal flow e.g. diuretics.
Previdni morate biti tudi pri sočasni uporabi s spojinami, ki vplivajo na pretok skozi ledvice, t.j. pri diuretikih.
Care should be exercised if applying Protopic to patients with extensive skin involvement over an extended period of time, especially in children (see section 4.2).
Previdnost je potrebna, če se zdravilo Protopic za dalj časa predpiše bolnikom z obsežno prizadetostjo kože, zlasti otrokom (glejte poglavje 4.2).
Care should be exercised in treating patients with active gastric or duodenal ulcers or patients predisposed to these conditions.
Pri zdravljenju bolnikov z aktivnimi razjedami želodca ali dvanajstnika, ali bolnikov, ki so k tem boleznim nagnjeni, je potrebna previdnost.
Care should be exercised not to apply the 500 mcg/g gel on the face or scalp as this could lead to a higher incidence of local skin responses.
Paziti je treba, da se na obraz ali lasišče ne nanaša gela z jakostjo 500 µg/g, ker to lahko privede do večje incidence lokalnih odzivov kože.
Care should be taken during use to avoid microbial contamination and spoilage.
Pazite tudi, da preprečite mikrobno kontaminacijo ali kvarjenje gela med njegovo uporabo.
Care should be taken if you drink alcohol while you are being treated with Duloxetine Lilly.
Bodite posebej previdni, če med zdravljenjem z zdravilom Duloxetine Lilly pijete alkohol.
Care should be taken in severe hepatic impairment as excessive dosing may increase the risk of adverse reactions, over-sedation or prolonged effect as a result of reduced dexmedetomidine clearance.
Potrebna je previdnost pri hudi jetrni okvari, ker prekomerno odmerjanje lahko poveča tveganje za neželene reakcije, preveliko sedacijo ali podaljšani učinek kot posledico zmanjšanega očistka deksmedetomidina.
Care should be taken not to bring the neonate into skin contact with areas to which Panretin has been recently applied.
Posebna pozornost je potrebna, da novorojenec s svojo kožo ne pride v stik s predeli kože bolnika(-ce), na katere je bil pred kratkim naneseno zdravilo Panretin gel.
Care should be taken to apply the dose to an area where the animal cannot lick it off (as described in section "Advice on correct administration"), and to ensure that animals do not groom each other immediately following treatment.
Paziti je potrebno, da se odmerek nanese na mesto, kjer ga žival ne more polizati (glej poglavje 9 "Nasvet o pravilni uporabi zdravila") ter, da se živali ne ližejo med seboj takoj po nanosu zdravila.
Care should be taken to apply the dose to an area where the animal cannot lick it off (see section 4.9), and to ensure that animals do not groom each other immediately following treatment.
Paziti je potrebno, da se odmerek nanese na mesto, kjer ga žival ne more polizati (glej poglavje 4.9), ter da se živali ne ližejo med seboj takoj po nanosu zdravila.
Care should be taken to apply the dose to an area where the animal cannot lick it off and to ensure that animals do not groom each other following treatment and that the content of the pipette or the applied dose does not come into contact with the eyes of the recipient and/or other animals.
Paziti je treba, da odmerek nanesete na področje, kjer ga žival ne more polizati in da živali ne čistijo druga drugi dlake takoj po zdravljenju in da vsebina merilne kapalke ali uporabljeni odmerek ne pride v stik z očmi zdravljene živali in/ali drugih živali.
Care should be taken to apply the dose to an area where the animal cannot lick it off, as described under section 4.9, and to ensure that animals do not groom each other immediately following treatment.
Paziti je treba, da odmerek nanesete na področje, kjer ga žival ne more polizati, kot je opisano v poglavju 4.9 in da živali ne čistijo druga drugi dlake takoj po zdravljenju.
Care should be taken to apply the veterinary medicinal product only onto intact skin.
Paziti je potrebno, da se zdravilo za uporabo v veterinarski medicini nanaša le na nepoškodovano kožo.
Care should be taken to apply the veterinary medicine only onto intact (undamaged) skin.
Paziti je potrebno, da se zdravilo za uporabo v veterinarski medicini nanaša le na nepoškodovano kožo.
Care should be taken to avoid bleeding.
Paziti je treba, da ne pride do krvavitve.
Care should be taken to avoid contact between the veterinary medicinal product and the eyes of the dog.
Izogibajte se stiku zdravila z očmi psa.
Care should be taken to avoid contact of the veterinary medicinal product with the eyes of the dog.
Paziti je treba, da zdravilo ne pride v stik z očmi psa.
Care should be taken to avoid contact with the eyes of the animal.
Paziti je treba, da zdravilo za uporabo v veterinarski medicini ne pride v oči psa.
Care should be taken to avoid inadvertent injection into a blood vessel.
Potrebna je previdnost, da ne pride do nenamernega injiciranja v krvno žilo.
Care should be taken to avoid spraying into the eyes of the animal.
Pri uporabi razpršila je treba paziti, da zdravilo ne pride živali v oči.
Care should be taken to avoid spread of the vaccine virus from vaccinated chickens to pheasants.
Paziti je treba, da se cepni virus ne bi s cepljenih piščancev prenesel na fazane.
Care should be taken to avoid spread of the vaccine virus from vaccinated chickens to pheasants.
Paziti je treba, da se cepni virus ne bi s cepljenih živali prenesel na fazane.
Care should be taken to ensure that the content of the pipette or the applied dose does not come into contact with the eyes of the recipient and/or other animals.
Paziti je treba, da vsebina merilne kapalke ali uporabljeni odmerek ne pride v stik z očmi zdravljene živali in/ali drugih živali.
Care should be taken to ensure that the contents of the pipette or the applied dose does not come into contact with the eyes or mouth of the recipient and/or other animals.
Poskrbite, da vsebina merilne kapalke ali nanešen odmerek ne pride v stik z očmi ali usti zdravljene živali in/ali drugih živali.
Care should be taken to ensure that the contents of the spot-on applicator, or the applied dose, do not come into contact with the eyes of the cat to be treated and/or any other animals.
Pazite, da zdravilo ne pride v oči mačke ali katerekoli druge živali.
Care should be taken to ensure that the tablet is ingested.
Zagotovite, da je bila odmerjena tableta zaužita.
Care should be taken to ensure the sterility of the prepared solution particularly as it contains no antimicrobial preservatives.
Pazite na sterilnost pripravljene raztopine, še zlasti ker ne vsebuje protimikrobnih konzervansov.
Care should be taken to ensure the sterility of the prepared solution particularly as it contains no preservatives.
Potrebna je previdnost, da se zagotovi sterilnost pripravljene raztopine, saj ne vsebuje konzervansov.
Care should be taken to select the correct size vial depending on the bodyweight of the dog.
Bodite pozorni na izbiro pravilne velikosti viale, kar je odvisno od telesne mase vašega psa.
Care should be taken to select the correct size vial depending on the weight of the dog.
Bodite pozorni na izbiro pravilne velikosti viale, kar je odvisno od telesne mase vašega psa.
Care should be taken when converting patients from ciclosporin-based to tacrolimus-based therapy (see sections 4.4 and 4.5).
Pri zamenjavi ciklosporinskega s takrolimskim zdravljenjem je potrebna previdnost (glejte poglavji in 4.5).
Care should be taken when dispensing SevoFlo, with immediate removal of any spillage.
Pri pripravi SevoFlo moramo biti previdni, morebitno razlito zdravilo je treba nemudoma odstraniti.
Care should be taken when dispensing Sevohale, with immediate removal of any spillage.
Pri pripravi Sevohalea moramo biti previdni, morebitno razlito zdravilo je treba nemudoma odstraniti.
Care should be taken when handling materials, such as bed linen, that come into contact with body fluids (such as spill of urine, faeces, vomiting etc.).
Previdnost je potrebna pri rokovanju z materiali kot je posteljnina, ki pridejo v stik s telesnimi tekočinami (npr. razlit seč, blato, bruhanje itd.).
Care should be taken with sun exposure by wearing protective clothing and /or sunscreen due to the potential risk of phototoxicity reactions associated with vandetanib treatment.
Previdnost je potrebna pri izpostavljenosti soncu zaradi možnosti fototoksičnih reakcij, povezanih z zdravljenjem z vandetanibom.
Care should be used when Opgenra is used in patients with renal or hepatic impairment (see section 4.4).
Pri uporabi zdravila Opgenra pri bolnikih z ledvično ali jetrno okvaro je potrebna previdnost (glejte poglavje 4.4).
Careful attention should be made to clinical signs/symptoms, tissue biopsies, and laboratory parameters.
Pozorno spremljajte tudi klinične znake/simptome, biopsije tkiv in laboratorijske parametre.
Careful clinical monitoring is advised in this group of patients (see sections 4.2 and 5.2).
Pri tej skupini bolnikov je priporočljivo natančno nadziranje (glejte poglavji 4.2 in 5.2).
Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients.
Količino uporabljene aktivnosti je treba skrbno pretehtati, saj je lahko pri teh bolnikih izpostavljenost sevanju večja.
Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients.
Količino uporabljene aktivnosti je treba skrbno pretehtati, saj je pri teh bolnikih izpostavljenost sevanju lahko večja.
Careful consideration should also be given to placing permanent skin covers (e.g. autografts) on deep partial thickness wounds soon after NexoBrid debridement.
Skrbno je treba razmisliti tudi o namestitvi trajnih kožnih prekritij (npr. avtotransplantatov) na globoke dermalne opekline takoj po čiščenju z zdravilom NexoBrid.